On January 31, 2024, Aclaris Therapeutics, Inc. terminated the employment of Gail Cawkwell, M.D., PhD., the Company's Chief Medical Officer, without cause, effective immediately.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.235 USD | +1.23% | -5.53% | +17.86% |
05-07 | Transcript : Aclaris Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
05-07 | Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q1 Revenue $2.4M, vs. Street Est of $2M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.86% | 86.94M | |
+24.26% | 46.71B | |
+48.83% | 41.8B | |
-0.95% | 41.52B | |
-5.86% | 29.55B | |
+11.06% | 25.78B | |
-20.27% | 19.26B | |
+2.76% | 12.14B | |
-3.63% | 12.08B | |
+29.49% | 11.98B |
- Stock Market
- Equities
- ACRS Stock
- News Aclaris Therapeutics, Inc.
- Aclaris Therapeutics, Inc. Announces Termination of Employment of Gail Cawkwell as Chief Medical Officer